Is the Sars-CoV-2 virus a possible trigger agent for the development of achalasia?

Janette Furuzawa-CarballedaMaría E Icaza-ChávezDiana Aguilar-LeónNorma Uribe-UribeMaría C Nuñez-PompaAlonso Trigos-DíazRodrigo Areán-SanzDheni A Fernández-CamargoEnrique Coss-Adame Miguel A ValdovinosEduardo Briceño-SouzaLuis A Chi-CerveraMiriam Olivares-FloresGonzalo Torres-Villalobos

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)

SARS-CoV2 and its receptor expression in the LESm of achalasia patients who posteriorly had COVID-19 but not in the controls suggests that it could affect the myenteric plexus. Unlike achalasia, patients-COVID-19 have an imbalance between effector CD4 T cells and the regulatory mechanisms.

Keyphrases

sars cov
respiratory syndrome coronavirus
end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
chronic kidney disease
transcription factor
dendritic cells
regulatory t cells
immune response
ultrasound guided
patient reported outcomes
patient reported